Glaukos logo

GlaukosNYSE: GKOS

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 June 2015

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$6.68 B
-12%vs. 3y high
90%vs. sector
-vs. 3y high
-vs. sector
-21%vs. 3y high
92%vs. sector
-12%vs. 3y high
84%vs. sector

Price

after hours | Tue, 05 Nov 2024 00:58:44 GMT
$121.49-$7.51(-5.82%)

Dividend

No data over the past 3 years
$95.69 M$91.49 M
$95.69 M-$50.55 M

Analysts recommendations

Institutional Ownership

GKOS Latest News

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript
seekingalpha.com04 November 2024 Sentiment: -

Call Start: 16:30 January 1, 0000 5:31 PM ET Glaukos Corporation. (NYSE:GKOS ) Q3 2024 Earnings Conference Call November 04, 2024, 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Lawrence Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Allen Gong - JPMorgan David Saxon - Needham Michael Sarcone - Jefferies Joanne Wuensch - Citigroup Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Welcome to Glaukos Corporation's Third Quarter 2024 Financial Results Conference Call.

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
zacks.com04 November 2024 Sentiment: POSITIVE

Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago.

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
zacks.com28 October 2024 Sentiment: POSITIVE

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
zacks.com17 October 2024 Sentiment: POSITIVE

Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.

Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?
zacks.com03 October 2024 Sentiment: POSITIVE

GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.

Glaukos Stocks Rides on Strong Product Demand Amid Competition
zacks.com11 September 2024 Sentiment: POSITIVE

GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
zacks.com09 September 2024 Sentiment: POSITIVE

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?
zacks.com22 August 2024 Sentiment: POSITIVE

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
zacks.com02 August 2024 Sentiment: POSITIVE

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
zacks.com01 August 2024 Sentiment: POSITIVE

Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.

What type of business is Glaukos?

Glaukos Corporation is a company specializing in ophthalmic medical technologies and pharmaceuticals, focusing on developing new methods for treating glaucoma, corneal diseases, and retinal diseases. The corporation was founded in 1998, with its headquarters in San Clemente, California. The company has developed micro-invasive glaucoma surgery (MIGS) as an alternative to traditional glaucoma treatment, and in 2012 launched its first MIGS device for sale. They have also developed a patented bioactivated pharmaceutical therapy for treating corneal disorders. Glaukos Corporation is involved in developing lines of surgical devices, pharmaceutical therapy, and implantable biosensors for treating the progression of glaucoma, corneal diseases such as keratoconus, dry eye, and a variety of other conditions.

What sector is Glaukos in?

Glaukos is in the Healthcare sector

What industry is Glaukos in?

Glaukos is in the Medical Devices industry

What country is Glaukos from?

Glaukos is headquartered in United States

When did Glaukos go public?

Glaukos initial public offering (IPO) was on 25 June 2015

What is Glaukos website?

https://www.glaukos.com

Is Glaukos in the S&P 500?

No, Glaukos is not included in the S&P 500 index

Is Glaukos in the NASDAQ 100?

No, Glaukos is not included in the NASDAQ 100 index

Is Glaukos in the Dow Jones?

No, Glaukos is not included in the Dow Jones index

When was Glaukos the previous earnings report?

No data

When does Glaukos earnings report?

Next earnings report date is not announced yet